Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11243
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPillay, Vinochanien
dc.contributor.authorGan, Hui Ken
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-16T00:49:55Z
dc.date.available2015-05-16T00:49:55Z
dc.date.issued2011-04-05en
dc.identifier.citationNew Biotechnology 2011; 28(5): 518-29en
dc.identifier.govdoc21473941en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11243en
dc.description.abstractMonoclonal antibodies (mAbs) have become one of the largest classes of new therapeutic agents approved for use in oncology, and have revolutionised the treatment of many human malignancies. Clinically useful mAbs can function through several different mechanisms, including inhibition of tumour-related signalling, induction of apoptosis, inhibition of angiogenesis, enhancing host immune response against cancer and targeted delivery of payloads (such as toxins, cytotoxic agents or radioisotopes) to the tumour site. The increasing knowledge of key molecules and cellular pathways involved in tumour induction and progression has led to a rise in the proportion of therapeutic mAbs entering clinical trials. These mAbs consist of various conventional or recombinant, murine, humanised, chimeric or fully human and fusion constructs. In this review, we provide an overview of mAbs approved for use in clinical oncology and those currently in clinical development. We also discuss the mechanisms of action of anti-cancer mAbs, as well as the antigen targets recognised by these antibodies.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Monoclonal.immunology.therapeutic useen
dc.subject.otherAntibodies, Neoplasm.immunologyen
dc.subject.otherAntigens, Neoplasm.immunologyen
dc.subject.otherAntineoplastic Agents.immunology.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherImmunologic Techniquesen
dc.subject.otherNeoplasms.drug therapy.immunologyen
dc.titleAntibodies in oncology.en
dc.typeJournal Articleen
dc.identifier.journaltitleNew biotechnologyen
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australiaen
dc.identifier.doi10.1016/j.nbt.2011.03.021en
dc.description.pages518-29en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21473941en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.